What can we offer to 3 million MDRTB household contacts in 2016?

BMC Medicine

Volumn 14, Issue 1, 2016, Pages

  Moore, David A J ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Household contacts; Latent tuberculosis infection; Multidrug resistant tuberculosis

Indexed keywords

DELAMANID; ISONIAZID; LEVOFLOXACIN; PLACEBO; TUBERCULOSTATIC AGENT;

CONTACT EXAMINATION; DRUG SENSITIVITY; EARLY DIAGNOSIS; HOUSEHOLD; HUMAN; LATENT TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; NOTE; TREATMENT OUTCOME; TUBERCULOSIS CONTROL; EARLY INTERVENTION; FAMILY SIZE; INFECTION CONTROL; PROCEDURES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; CONTACT TRACING; EARLY DIAGNOSIS; EARLY MEDICAL INTERVENTION; FAMILY CHARACTERISTICS; HUMANS; INFECTION CONTROL; LATENT TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85007415214     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-016-0610-x     Document Type: Note

References (23)

1. Organisation WH. 2015 Global tuberculosis report. Geneva, 2015.
2. Organisation WH. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, 2014.
3. Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182(5):684-92.
4. Organisation WH. The use of bedaquiline in the treatment of multidrugresistant tuberculosis. Geneva, 2013.
5. Organisation WH. The use of delamanid in the treatment of multidrugresistant tuberculosis-interim policy guidance. Geneva, 2014.
6. Grandjean L, Crossa A, Gilman RH, et al. Tuberculosis in household contacts of multidrug-resistant tuberculosis patients. Int J Tuberc Lung Dis. 2011;15(9):1164-9. i.
7. Grandjean L, Gilman RH, Martin L, et al. Transmission of Multidrug-Resistant and Drug-Susceptible Tuberculosis within Households: A Prospective Cohort Study. PLoS Med. 2015;12(6):e1001843. discussion e.
8. Organisation WH. Recommendations for investigating contacts of persons with infectious tuberculosis in low-and middle-income countries. 2012.
9. Organisation WH. Guidelines on the management of latent tuberculosis infection. Geneva; 2015.
10. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 2000, (2): CD001363.
11. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9777):1588-98.
12. Houben RM, Sumner T, Grant AD, White RG. Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings. Proc Natl Acad Sci U S A. 2014;111(14):5325-30.
13. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010, (1): CD000171.
14. Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebocontrolled trial. Lancet. 2014;384(9944):682-90.
15. Durovni B, Cavalcante SC, Saraceni V, et al. The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study. AIDS. 2010;24 Suppl 5:S49-56.
16. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009;13(11):1320-30.
17. Cohen T, Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med. 2004;10(10):1117-21.
18. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science. 2006;312(5782):1944-6.
19. Shah NS, Yuen CM, Heo M, Tolman AW, Becerra MC. Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2014;58(3):381-91.
20. Goldman JA, Kearns GL. Fluoroquinolone use in paediatrics: focus on safety and place in therapy, 2011.
21. Sarathy J, Dartois V, Dick T, Gengenbacher M. Reduced drug uptake in phenotypically resistant nutrient-starved nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2013;57(4):1648-53.
22. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011; 365(23):2155-66.
23. Seddon JA, Fred D, Amanullah F, et al. Post-exposure management of multidrug-resistant tuberculosis contacts: evidence-based recommendations. Dubai, UAE: Harvard Medical School Centre for Global Health Delivery-Dubai, 2015.